Zimmer Biomet Reports Solid Q3 2024 Performance
Company Announcements

Zimmer Biomet Reports Solid Q3 2024 Performance

Zimmer Biomet Holdings ( (ZBH) ) has realeased its Q3 earnings. Here is a breakdown of the information Zimmer Biomet Holdings presented to its investors.

Zimmer Biomet Holdings, Inc. is a global leader in medical technology that specializes in creating solutions for improving mobility and overall health, leveraging advanced digital and robotic technologies to enhance patient care.

In its recent earnings report for the third quarter of 2024, Zimmer Biomet reported net sales of $1.824 billion, reflecting a growth of 4.0% compared to the previous year. The company’s adjusted earnings per share stood at $1.74, showcasing resilience despite challenges posed by ERP implementation issues.

Key financial highlights include a robust performance in international markets, with sales growing by 6.9% and notable category growth in knees and hips. Strategically, the company announced the commercial launch of the Z1 Femoral Hip System and the acquisition of OrthoGrid Systems Inc., expanding its portfolio in AI-driven surgical guidance systems. The company has also narrowed its full-year financial guidance, adjusting its revenue growth expectations slightly downward.

Looking ahead, Zimmer Biomet remains focused on its strategic priorities to drive innovation and product introductions, aiming to address global unmet medical needs while navigating operational challenges with a commitment to enhancing patient outcomes.

Related Articles
TheFlyZimmer Biomet cuts FY24 adjusted EPS view to $7.95-$8.05 from $8.00-$8.15
TheFlyZimmer Biomet reports Q3 adjusted EPS $1.74, consensus $1.73
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App